Skip to content

Author

M. Yılmaz

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Mucosal, Ocular, and Pulmonary Adverse Events Reported with Datopotamab Deruxtecan: An Indication-Restricted Disproportionality Analysis of the FDA Adverse Event Reporting System

Background/Objectives: Datopotamab deruxtecan was approved in 2025 for hormone receptor-positive, HER2-negative metastatic breast cancer and for EGFR-mutated non-small cell lung cancer (NSCLC); its safety profile in routine use has not been described. We characterized adverse event reporting for the agent and asked whe...

Osman Bilge Kaya, B. Karabuğa, E. Aydemir et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.